Canada Markets closed

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
33.05+0.76 (+2.35%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close32.29
Open32.67
Bid30.00 x 1000
Ask33.25 x 800
Day's Range32.26 - 33.41
52 Week Range20.40 - 54.85
Volume114,704
Avg. Volume278,098
Market Cap1.54B
Beta (5Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update

    Updated complete and durable response data in RP1 (vusolimogene oderparepvec) skin cancer cohorts support the ongoing registration directed development programs in CSCC and anti-PD-1 failed melanoma, with full accrual for both programs expected in mid-2022 Initial data with RP2 as monotherapy and in combination with Opdivo® (nivolumab) in patients with difficult-to-treat and anti-PD-1 failed cancers supports expanding the Phase 1 clinical trial to focus on patients whose tumors have metastasized

  • GlobeNewswire

    Replimune to Present at Two Upcoming Investor Conferences

    WOBURN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences: BTIG Virtual Biotechnology Conference 2021Date: Monday, August 9, 2021Presentation Time: 11:00 am ET 2021 Wedbush PacGrow Healthcare Virtual ConferencePanel: For Your IOn

  • GlobeNewswire

    Replimune to Present at the William Blair Biotech Focus Conference 2021

    WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced that Robert Coffin, Ph.D., President and Chief Research & Development Officer of Replimune, will participate in a panel titled “Novel Mechanisms and Strategies for Addressing PD-(L)1 Refractory/Resistant Tumors” at the William Blair Biotech Focus Conference 2021 taking place virtually on Wed